Vir Biotechnology, Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Vir Biotechnology, Inc. (VIR) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $10.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-08-05
- Vir Biotechnology, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-06-30 was $10.28M.
- Vir Biotechnology, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-03-31 was $10.15K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month |
|---|---|---|
| 2026-06-30 | $10.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.29M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $10.15K 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |